By targeting a protein crucial in the early development of the brain, researchers discovered that they can block multiple signaling pathways implicated in glioblastoma growth and have reduced human tumors in mouse models of the disease.
Glioblastoma is a complex, deadly, and hard-to-treat brain cancer, but Yale School of Medicine researchers may have found the tumor’s Achilles heel.
The researchers report in the August 12 issue of the journal Science Signaling that targeting a protein crucial in the early development of the brain can block multiple signaling pathways implicated in glioblastoma growth. The approach also reduced human tumors in mouse models of the disease.
“In neurodevelopment, this protein (atypical protein kinase or aPKC) helps regulate proliferation and migration of cells but when active in adults, can cause the formation and spread of cancer,” said Sourav Ghosh, assistant professor of neurology and co-senior author of the paper.
About 13,000 people die of primary malignant brain tumors annually in the United States. Glioblastomas are particularly hard to treat because these tumors grow rapidly, spread quickly, and respond poorly to current anti-tumor therapies.
The new study shows that targeting this protein works in several ways. Inhibiting aPKC blocks a signal pathway that is the target of existing glioblastoma therapy. But it also blocks the action of some immune system cells called macrophages, which instead of attacking tumors, actively promote their growth.
“This is exciting because it ends up targeting multiple pathways involved in cancer,” said Carla Rothlin, assistant professor of immunobiology and co-senior author of the paper.
The work was funded by the National Institutes of Health.
Yael Kusne of Arizona State University and Eugenio Carrera-Silva, of Yale are co-lead authors of the paper.
Reference: “Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma” by Yael Kusne, Eugenio A. Carrera-Silva, Anthony S. Perry, Elisabeth J. Rushing, Edward K. Mandell, Justin D. Dietrich, Andrea E. Errasti, Daniel Gibbs, Michael E. Berens, Joseph C. Loftus, Christopher Hulme, Weiwei Yang, Zhimin Lu, Kenneth Aldape, Nader Sanai, Carla V. Rothlin and Sourav Ghosh, 12 August 2014, Science Signaling.
DOI: 10.1126/scisignal.2005196
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.
1 Comment
THE NEW CURE FORMED BY EXCELLERATIONS OF CELLUAR-DECREASED BY EACH/ SERIES OF THE INJECTIONS OF ERTHYCILLINN AND AMOXYLLILN IS THESE COLLECTIONS ARE DUE TO THESE COMBINATIONS OF THE FORMS OF CELLS INJECTIONS COMBIANED EXCELLERATES THE CELLUAR-COMPENSATIONS OF THE BRAIN DAMAGE REFUSED BY EACH VIRTUES OF COMMON-SENSE INTO THESE COLLECTIONS ARE DUE TO THESE COMBINATIONS OFTEN RESULTS OF (BIO-NEUROLOGY) A CONNECTIONS OF DIABILITES OF ALL PATIENTS AND DEFINITONS ARE DEVELOPEMNETS ANNALYSIS AND EVEN THOUGHTS OF POSITIVITY AND SERIES OF THE FOLLOWING DUE TO ITS REPLACES A SIMPLE ISSUES ARE COMPLETED BY THE ADVANCEMENTS OF EVERYTHING IS VALUES INTO THE FOLLOWING INTO THESE QUESTIONS OF (“CCC”)COMBINATION/ COLLECTIONS/COMPENSATIONS ARE THE VALUES A SIMPLE DEFINTIONS DECREASED AND DEVELOPED INTO THESE QUESTIONS OF DOUBTS INTO THESE QUESTIONS INNER-ISSUES ARE COLLECTIONS ASSOICATES WITH ALL PROCESSED COMBINATIONS ALL ASSUMPTIONS ENERGY INTO THESE QUESTIONS OFTEN REVISED AND DESCRIPITONS ARE SIMPLE ISSUES.